[Thrombolytic therapy in acute lower extremity ischemia]. 1996

P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
Karkirurgisk afdeling RK, Rigshospitalet, København.

During a period of four and a half years 37 lower extremities with acute ischaemia were treated with thrombolysis. Angiographically, 35 cases demonstrated no suitable arteries for distal reconstruction. In two cases vascular surgery was not performed because of cardiac incompensation. Two patients died within one month and limb salvage was 69%. During 22 months (3-48) of follow-up another six patients were amputated two to nine months later. The 18 salvaged lower extremities (49%) had an ankle-brachial pressure index of 0.63 (0.30-1.-09). Review of all angiograms revealed a demonstrable effect of thrombolytic therapy only in 13 (35%) cases. In conclusion, thrombolytic therapy should be considered in the case of acute lower extremity ischaemia unsuitable for reconstructive procedures. Even though the effect of thrombolytic therapy cannot be demonstrated on the angiogram, that should not necessarily deem the treatment to be a failure.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007866 Leg The inferior part of the lower extremity between the KNEE and the ANKLE. Legs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D001807 Blood Vessel Prosthesis Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels. Vascular Prosthesis,Blood Vessel Prostheses,Tissue-Engineered Vascular Graft,Graft, Tissue-Engineered Vascular,Grafts, Tissue-Engineered Vascular,Prostheses, Blood Vessel,Prostheses, Vascular,Prosthesis, Blood Vessel,Prosthesis, Vascular,Tissue Engineered Vascular Graft,Tissue-Engineered Vascular Grafts,Vascular Graft, Tissue-Engineered,Vascular Grafts, Tissue-Engineered,Vascular Prostheses,Vessel Prostheses, Blood,Vessel Prosthesis, Blood
D005260 Female Females
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic

Related Publications

P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
May 1993, Journal of vascular surgery,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
February 2019, Vascular,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
January 1996, Seminars in thrombosis and hemostasis,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
February 2000, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
January 1993, Journal of vascular and interventional radiology : JVIR,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
May 1993, Annals of vascular surgery,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
January 1992, Polski tygodnik lekarski (Warsaw, Poland : 1960),
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
February 1996, Ugeskrift for laeger,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
August 1998, American journal of surgery,
P Rørdam, and M T Enevoldsen, and J B Grønvall Rasmussen, and N O Laursen, and M K Hensler, and P V Madsen, and T V Schroeder
March 1997, Seminars in vascular surgery,
Copied contents to your clipboard!